866-997-4948(US-Canada Toll Free)

Global Lymphoma Drugs Market 2017-2021

Published By :

Technavio

Published Date : Jun 2017

Category :

Oncology

No. of Pages : 86 Pages

About Lymphoma Drugs
Lymphoma is a type of cancer that affects the immune system of the body. Specifically, it affects the lymphocytes, a type of white blood cell. The lymphocytes are part of the immune system and help the body to fight infections. The cancerous lymphocytes grow uncontrollably and collect in different portions of the body; lymph node can be one of the most common sites for lymphoma development. The lymph nodes are found throughout the body particularly in the groin, neck, and under the arms. Lymphoma can also develop in the deeper lymph nodes such as those in bone marrow and spleen. Very rarely this disease can start in other parts of the body such as stomach, breast, skin, brain, bowel, or liver.

Technavios analysts forecast the global lymphoma drugs market to grow at a CAGR of 8.02% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global lymphoma drugs market for 2017-2021. To calculate the market size, the report considers the sales from branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Lymphoma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Celgene
F. Hoffmann-La Roche
Johnson & Johnson
Seattle Genetics
Other prominent vendors
Amgen
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
Novartis
Pfizer
Takeda Pharmaceuticals
Teva Pharmaceutical Industries
Market driver
Increase in industry-academia collaborations
For a full, detailed list, view our report

Market challenge
High cost of lymphoma treatment
For a full, detailed list, view our report

Market trend
Increasing consolidation in the cancer treatment market
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.




Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
Market outline
Lymphoma disease overview
PART 05: Market Introduction
Market overview
Market size and forecast
Five forces analysis
PART 06: Pipeline landscape
PART 07: Market segmentation by disease type
HL
NHL
PART 08: Geographical segmentation
Lymphoma drugs market in Americas
Lymphoma drugs market in EMEA
Lymphoma drugs market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
Market drivers
Market challenges
PART 11: Market trends
Increasing consolidation in the cancer treatment market
Development of rituximab resistance leading to the development of new therapies
Studies performed to understand the genetics of lymphoma cells
PART 12: Vendor landscape
Competitive scenario
PART 13: Key vendor analysis
Celgene
F. Hoffmann-La Roche
Johnson & Johnson
Seattle Genetics
Other prominent vendors
PART 14: Appendix
List of abbreviations
List of Exhibits
Exhibit 01: Types of lymphoma
Exhibit 02: Tests for lymphoma
Exhibit 03: Stages of lymphoma development
Exhibit 04: Treatment options for lymphoma
Exhibit 05: Global lymphoma drugs market snapshot
Exhibit 06: Global lymphoma drugs market 2016-2021($ millions)
Exhibit 07: Opportunity analysis in global lymphoma drugs market
Exhibit 08: Five forces analysis
Exhibit 09: Key pipeline drugs by vendors
Exhibit 10: Pipeline analysis
Exhibit 11: Segmentation of global lymphoma drugs market by disease type 2016
Exhibit 12: Market share of global lymphoma drugs market based on disease type 2016 and 2021
Exhibit 13: Subtypes of HL
Exhibit 14: Types of classic HL
Exhibit 15: Global HL drugs market 2016-2021 ($ millions)
Exhibit 16: Major drugs involved in HL drugs market
Exhibit 17: Types of NHL
Exhibit 18: Prevalence of various B-cell lymphoma in NHL
Exhibit 19: T-cell and natural killer cell lymphoma types
Exhibit 20: Global NHL drugs market 2016-2021 ($ millions)
Exhibit 21: Key highlights of NHL drugs market
Exhibit 22: Segmentation of global lymphoma drugs market based on geography 2016 and 2021
Exhibit 23: Global lymphoma drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 24: Market scenario in Americas
Exhibit 25: Lymphoma drugs market in Americas 2016-2021 ($ millions)
Exhibit 26: Incidence of NHL in Americas
Exhibit 27: Market scenario in EMEA
Exhibit 28: Lymphoma drugs market in EMEA 2016-2021 ($ millions)
Exhibit 29: Lymphoma cases in UK 2014
Exhibit 30: Incidence of NHL in EMEA
Exhibit 31: Market scenario in APAC
Exhibit 32: Lymphoma drugs market in APAC 2016-2021 ($ millions)
Exhibit 33: Incidence of NHL in APAC
Exhibit 34: Grants for research projects for NHL compared with total cancer researches 2016
Exhibit 35: Drugs and associated side effects
Exhibit 36: Competitive structure analysis of global lymphoma drugs market 2016
Exhibit 37: Strategic success factors of companies in global lymphoma drugs market
Exhibit 38: Celgene: Key highlights
Exhibit 39: Celgene: Strength assessment
Exhibit 40: Celgene: Strategy assessment
Exhibit 41: Celgene: Opportunity assessment
Exhibit 42: F. Hoffmann-La Roche: Key highlights
Exhibit 43: F. Hoffmann-La Roche: Strength assessment
Exhibit 44: F. Hoffmann-La Roche: Strategy assessment
Exhibit 45: Johnson & Johnson: Opportunity assessment
Exhibit 46: Johnson & Johnson: Key highlights
Exhibit 47: Johnson & Johnson: Strength assessment
Exhibit 48: Johnson & Johnson: Strategy assessment
Exhibit 49: Johnson & Johnson: Opportunity assessment
Exhibit 50: Seattle Genetics: Key highlights
Exhibit 51: Seattle Genetics: Strength assessment
Exhibit 52: Seattle Genetics: Strategy assessment
Exhibit 53: Seattle Genetics: Opportunity assessment

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *